Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 733

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 733
---
 Diabetes in these seven countries in 2021 was estimated by the IDF as approximately 67 million with an estimated total growth of 5.1% by 2023 to approximately 70.4 million. Stem Cell Therapies Prices Over the past 3 years, drug manufacturers have disrupted the medical and prescription drug industries considerably with the rapid growth of cellular therapies. Often lifesaving, these therapies represent a promising new era for medical treatments in the US. However, the high cost and growing pipeline for cell therapies present considerable challenges for the US medical insurance market. As the number of approved cell therapies continues to grow, the impact on insurance claim activity is a paramount challenge for employers, insurers and reinsurers. The eligible population to receive these therapies is still relatively small, so while currently approved therapies have not yet become a significant percentage of overall US medical spend, claim frequency is slowly building. The exact stem cell treatment cost can be determined only after careful evaluation of the case and other parameters associated with the treatment. For example, the stem cell therapy cost is influenced by several factors, including the type, quality, and source of stem cells, the condition to be treated, and the location of the treatment facility. In addition, the number of cells to be administered and whether the stem cells are ethically sourced and viable also influence stem cell therapy price. Following is a list of FDA approved cell therapies and their cost as of June 30, 2023, 4:

| Drug     |     | Condition                    |     | Manufacturer          |     | Cost ($000’) |
| Abecma   |     | Multiple Myeloma             |     | Celegene              |     |        419.5 |
| Breyanzi |     | Large B-Cell Lymphoma        |     | Juno Therapeutics     |     |        410.3 |
| Carvykti |     | Multiple Myeloma             |     | Janssen Biotech       |     |        465.0 |
| Kymriah  |     | Follicular Lymphoma          |     | Novartis              |     |        475.0 |
| Lantidra |     | Type 1 Diabetes              |     | CellTrans             |     |        300.0 |
| Maci     |     | Knee/Joint defects           |     | Vericel               |     |         40.0 |
| Omisirge |     | Blood Cancers                |     | Gam